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Abstract
The effect of tuberculosis on mortality in people initiating highly active antiretroviral treatment
(HAART) remains unclear; here, we strengthened a previous cohort analysis. Multivariate Cox
proportional hazards models were used to assess the association of baseline tuberculosis and time
to all-cause mortality among HAART initiators. In reanalysis, treatment for tuberculosis at time of
HAART initiation remained unassociated with increased risks of all-cause mortality, with adjusted
hazard ratios ranging from 1.00 to 1.09.
In 2010, Straetemans et al. published a meta-analysis of the effect of tuberculosis on
mortality in HIV positive people[1]. In a sub-analysis of six studies, they found an overall
hazard ratio of 1.08 (95% confidence limits 0.91, 1.27) for the effect of TB on all-cause
mortality in HIV-positive individuals where at least 50% of the cohort reported use of
HAART. Nonetheless the authors concluded that insufficient data were available to draw
strong conclusions about the effect of TB on all-cause mortality among individuals receiving
HAART. The largest contributor to that sub-analysis was a 2009 report in this journal by
Westreich et al., which examined the effect of prevalent pulmonary tuberculosis being
treated at time of HAART initiation on time to mortality among patients all of whom were
initiating HAART in Johannesburg, South Africa[2]. We found an adjusted (weighted)
hazard ratio of 1.06 (95% confidence limits 0.75, 1.49) in these individuals, indicating no
increased risk of death among those with prevalent tuberculosis at time of HAART
initiation.
While our findings were in line with that of at least some other studies[1, 3–5], our study
had two, related limitations. First, there was a high rate of loss to follow-up in our study;
second, we had a low recorded incidence of mortality. We attempted to account for these
effects[2] by using inverse probability of censoring weights[6]. However, inverse
probability of censoring weights rely on assumptions that data are censored (missing) at
random[7–9], an assumption which, similar to an assumption of no uncontrolled
confounding[10], is not verifiable. Since the publication of our report, additional mortality
information has been obtained from the South African National Death Registry[11] for a
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subset of patients in the database. This allowed an opportunity to enhance our analysis with
better mortality data[11], extend follow-up by 18 months, and check the validity of
modeling assumptions and overall results from the original publication in three analyses.
Details on TB screening, treatment for TB and HIV at the Themba Lethu Clinic and South
Africa more generally, and on clinical care and research procedures of the clinic has been
described in detail [2, 11, 12]. In the original cohort analysis, we examined impact of being
in treatment for TB at baseline (initiation of HAART) on time to all-cause mortality among
all patients initiating HAART at the Themba Lethu Clinic between 1 April 2004 and 31
March 2007[11]. In the updated analysis, we used the same set of individuals and same
time-frame, but updated vital status outcomes and dates of death. In the extended analysis,
we extended follow-up (including opportunity for death) until 1 October 2008, allowing up
to 18 additional months of follow-up in all subjects. In the original report[2] we found no
changes in estimates of effect when using inverse probability of censoring weights[6]
compared to traditional adjusted Cox proportional hazards models, so these analyses used
traditional Cox models, adjusted for confounding by factors as in the original report[2].
Results from reanalysis are summarized in the Table. In the original cohort, the 7,512
subjects in the database experienced a recorded 298 deaths, 74 (25%) of which were in
subjects exposed to prevalent TB. There were 1,423 subjects recorded as lost to follow-up.
The crude hazard ratio (HR) was 1.68 (95% CL 1.29, 2.19), and the adjusted was 1.07 (95%
CL 0.80, 1.44). These are nearly identical to the originally reported results[2].
In the updated cohort, among 7,512 subjects there were 494 deaths recorded, of which 115
(23%) occurred in prevalent TB cases; and there were 882 subjects recorded as lost to
follow-up. The crude HR was 1.55 (95% CL 1.26, 1.91), and the adjusted was 1.00 (95% CL
0.80, 1.26).
In the extended cohort, among 7,512 subjects there were 666 deaths, of which 155 (23%)
occurred in prevalent TB cases. There were 1,460 subjects recorded as lost to follow-up. The
crude HR was 1.62 (95% CL 1.35, 1.94), and the adjusted HR was 1.09 (95% CL 0.90,
1.33).
This reanalysis of data from a large cohort of individuals initiating HAART in South Africa
reaffirms earlier findings[2] that patients receiving active treatment for tuberculosis at
HAART initiation were not at higher risk of death compared to those not being treated for
TB, demonstrating that these findings were robust to more-complete collection of previously
missing data. One limitation of this reanalysis is that Fox et al. were able to obtain vital
registration data for only 42% of subjects presumed lost to follow-up [11]. Thus, more than
50% of those lost to follow-up may have in fact not had their vital status validated.
Nonetheless, reanalysis only among those patients with valid medical ID numbers (those
whose status would have been evaluated by Fox et al. if they had been presumed lost to
follow-up; about 64% of all patients) yielded very similar results, with HR=0.90 (95% CL
0.68, 1.20) in the updated cohort and HR=1.01 (95% CL 0.79, 1.29) in the extended cohort.
High rates of patients becoming lost to follow-up are an unfortunate reality in both the
practice and analysis of large-scale HIV clinical cohorts[13], and the missing data which
results from these losses can be a significant challenge to the validity of the results of
analyses in those cohorts[14–16]. When that missing data comprises missing outcome
values which are caused by the true value of the missing outcomes, not only are biased
effect estimates likely [17], but the bias cannot generally be eliminated through analytic
approaches such as inverse probability of censoring weights or multiple imputation[17]
(although these approaches[18] as well as others[14–16] may help reduce bias). However,
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this bias will not be introduced when the true effect is null[17]; as this re-analysis
demonstrates, the true effect is likely to be null, and our original report was likely unbiased.
In conclusion, our analysis substantially strengthens the evidence that TB treatment at time
of HAART initiations is not associated with increased risk of mortality on HAART.
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Table
Summary of results from re-analyses of effect of treated tuberculosis on all-cause mortality among subjects
initiating HAART in Johannesburg, South Africa.
Scenario Deaths
Hazard ratio (95% confidence limits)
Crude Adjusted
Original cohort analysis 298 1.68 (1.29, 2.19) 1.07 (0.80, 1.44)
Updated analysis 494 1.55 (1.26, 1.91) 1.00 (0.80, 1.26)
Extended analysis 666 1.62 (1.35, 1.94) 1.09 (0.90, 1.33)
HR, hazard ratio. CL, confidence limit.
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